Home Featured Page 302

Featured

Latest

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies...

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

PTSF50 – Microdosing and the Placebo Effect, with Balázs Szigeti and...

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment...

Octarine Bio announces closing of extended seed round financing of $1.2...

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using...

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for...

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a...

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier

EDITOR PICKS

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies...

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

PTSF50 – Microdosing and the Placebo Effect, with Balázs Szigeti and...

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment...

Octarine Bio announces closing of extended seed round financing of $1.2...

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using...

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for...

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a...

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier

EDITOR PICKS

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY